APOB and metabolic dysfunction-associated steatohepatitis: The cirrhotic NASH patents also showed lower hepatic fat than noncirrhotic NASH patients (Table 1 and supplemental Fig. S2B), which might lower apoB secretion (5, 6, 7, 41).